Table 4 Severity of standard of care treatment-emergent adverse events.

From: LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

TEAE, n (%)a

N = 248

Any TEAE

207 (83.5)

Any serious TEAE

84 (33.9)

Maximum severity of TEAE

 

 Grade 1

16 (6.5)

 Grade 2

52 (21.0)

 Grade 3

78 (31.5)

 Grade 4

44 (17.7)

 Grade 5

17 (6.9)

TEAE with outcome death

19 (7.7)

  1. TEAE treatment-emergent adverse event.
  2. aPercentages are calculated with the all-treated analysis set as denominator.
Back to article page